Exhibit 99.1
Alere Reports Third Quarter 2015 Financial Results
WALTHAM, Mass., November 4, 2015 – Alere Inc. (NYSE: ALR), a global leader in rapid diagnostic tests, today announced its financial results for the quarter ended September 30, 2015. Net revenue for the third quarter of 2015 was $602.0 million, a 7.3 percent decrease compared to $649.2 million in the third quarter of 2014, or a 1.7 percent decrease in organic growth, which is on a constant currency basis, excluding impacts of acquisitions and divestitures. Net income from continuing operations available to common stockholders was $0.2 million, or $0.00 per diluted share, in the third quarter of 2015. On a non-GAAP basis, the Company reported non-GAAP adjusted net income from continuing operations available to common stockholders of $48.3 million, or $0.54 per diluted share, in the third quarter of 2015.
Net Revenue (in millions) | Third Quarter 2015 | Third Quarter 2014 (1) | % Change | |||||||||
Cardiometabolic Disease | $ | 208 | $ | 208 | — | |||||||
Infectious Disease | $ | 164 | $ | 184 | (11 | ) | ||||||
Toxicology | $ | 163 | $ | 167 | (2 | ) | ||||||
Other | $ | 45 | $ | 65 | (30 | ) | ||||||
Consumer Diagnostics | $ | 19 | $ | 21 | (12 | ) | ||||||
License and Royalty | $ | 3 | $ | 4 | (21 | ) | ||||||
|
|
|
|
|
| |||||||
Total | $ | 602 | $ | 649 | (7 | ) | ||||||
|
|
|
|
|
| |||||||
| (1) | Revenues, other than License and Royalty, have been reclassified due to a change in segment reporting as a result of the divestiture of our health management business in 2015 and the results of our patient self-testing business are primarily included within Cardiometabolic Disease. |
“Third quarter revenue was impacted by currency and lower international sales. Europe organic growth declined by 4 percent and tender awards in Africa and Asia have taken longer to ramp than anticipated; however, we expect both Africa and Asia to contribute to near-term growth,” said Namal Nawana, CEO of Alere. “Pain management and INRatio revenue declined year-over-year and negatively impacted our profitability in the third quarter; however, excluding pain management, our core Toxicology revenue grew by 6% during the third quarter, which represents 10 consecutive quarters of organic growth. Despite these short-term challenges, our core businesses and platforms had solid growth and we gained significant traction with the launch of Alere i, with revenue of $5 million in the third quarter and total worldwide placements of more than 2,800 instruments to date.
From an operational perspective, we exercised strong operating expense discipline and delivered third quarter non-GAAP EPS growth of 54 percent year-over-year. Looking ahead, we expect fourth quarter 2015 revenue to rebound and we are re-doubling our efforts to establish solid and sustainable organic growth for Alere. We are confident that the strength of our core platforms will eclipse near-term challenges and accelerate our overall growth. The Alere team is fully focused on continuing to execute against our strategic growth initiatives to deliver enhanced value for our shareholders.”
Third Quarter Highlights
| • | Alere receives FDA CLIA Waiver for Alere™ i Strep A Rapid Molecular Test |
| • | Alere Agrees to Sell BBI Group and Acquires US Diagnostics |
| • | Dr. Geoffrey S. Ginsburg Joins Alere Board |
Third Quarter 2015 Results
Third quarter 2015 net revenue of $602.0 million declined by $47.2 million from $649.2 million, or 7.3 percent, compared to the prior year period, primarily due to a $33.0 million negative impact from foreign currency exchange; a $12.6 million decrease in pain management; and a $7.7 million decrease in global sales of INRatio. In addition, BBI revenue and contract manufacturing revenue associated with our consumer joint venture declined by $8.7 million and CD4 and malaria sales in Africa decreased by $8.0 million during the third quarter. Growth areas included: patient self-testing, Afinion and epoc in Cardiometabolic Disease; dengue in Infectious Disease; and employer services and reagents in Toxicology. Global influenza sales were $19.6 million in the third quarter of 2015, a 15.9 percent increase over the prior year period, including approximately $4.9 million in Alere i sales.
Gross profit in the third quarter of 2015 was $275.0 million, with 45.7 percent gross margin, compared to $301.6 million in the third quarter of 2014, with 46.5 percent gross margin. Non-GAAP adjusted gross profit in the third quarter of 2015 was $292.5 million, with 48.5 percent non-GAAP adjusted gross margin, compared to $323.6 million in the third quarter of 2014, with 49.8 percent non-GAAP adjusted gross margin. Non-GAAP adjusted gross profit excludes amortization of acquisition-related intangibles, restructuring charges, and stock-based compensation.
Operating expenses were $245.9 million, or 40.8 percent of net revenue, in the third quarter of 2015, compared to operating expenses of $266.3 million, or 41.0 percent of net revenue, in the third quarter of 2014. Included in the third quarter 2015 operating expenses was R&D expense of $36.0 million, or 6.0 percent of net revenue, and SG&A expense of $207.8 million, or 34.5 percent of net revenue. Also included in the third quarter 2015 operating expenses were $2.1 million in net charges related to impairment and loss on dispositions. Non-GAAP adjusted operating expenses during the third quarter of 2015 were $187.0 million, or 31.0 percent of net revenue, and were comprised of $27.4 million of non-GAAP adjusted R&D expense, or 4.5 percent of net revenue, and non-GAAP adjusted SG&A expense of $159.6 million, or 26.5 percent of net revenue. Non-GAAP adjusted operating expenses, non-GAAP adjusted R&D expenses and non-GAAP adjusted SG&A expense exclude, as applicable, amortization of acquisition-related intangibles, restructuring charges, stock-based compensation, fair value adjustments to contingent consideration, compensation costs associated with contingent consideration, costs associated with business dispositions, and impairment and loss on dispositions, net.
Page 2 of 5
Operating income was $29.2 million in the third quarter of 2015, compared to operating income of $35.3 million in the third quarter of 2014. Non-GAAP adjusted operating income was $105.4 million in the third quarter of 2015, compared to non-GAAP adjusted operating income of $116.6 million in the third quarter of 2014.
Net income from continuing operations available to common stockholders was $0.2 million, or $0.00 per diluted share, in the third quarter of 2015, compared to a net loss from continuing operations available to common stockholders of $89.4 million, or $1.08 per diluted share, in the third quarter of 2014. On a non-GAAP basis, the Company reported non-GAAP adjusted net income from continuing operations available to common stockholders of $48.3 million, or $0.54 per diluted share, in the third quarter of 2015, compared to non-GAAP adjusted net income from continuing operations available to common stockholders of $30.0 million, or $0.35 per diluted share, in the third quarter of 2014.
Financial results for the three- and nine-month periods of 2015 and the comparable three- and nine-month periods of 2014 are included in the schedules to this press release.
Detailed reconciliations of the non-GAAP financial measures presented in this release to the most directly comparable financial measures under GAAP, as well as a discussion regarding these non-GAAP financial measures, are included in the schedules to this press release.
2015 Business Outlook
For the year ending December 31, 2015, the Company expects:
| • | Net revenue to be in the range of $2.48 billion to $2.50 billion |
| • | Non-GAAP adjusted net income from continuing operations available to common stockholders in the range of $2.20 to $2.25 per diluted common share |
Conference Call
We will host a conference call beginning at 5:00 p.m. (Eastern Time) today, November 4, 2015, to discuss these results, as well as other company matters. During the conference call, we may answer questions concerning business and financial developments and trends and other business and financial matters. Our responses to these questions, as well as other matters discussed during the conference call, may contain or constitute material information that has not been previously disclosed.
A live webcast will be available on the Investor Relations section of Alere’s website, or accessed directly through the following link:https://www.webcaster4.com/Webcast/Page/411/11453
To access the audio conference call, please use the following dial-in numbers and access code 5625983:
| • | US (toll-free): 1-888-317-6003 |
| • | International: 1-412-317-6061 |
| • | Canada (toll-free): 1-866-284-3684 |
Page 3 of 5
A replay will be available approximately one hour after the conclusion of the call and will remain available for a period of seven days following the call. To hear a replay of the conference call, please use the following dial-in numbers and replay code 10075496 (available for seven days):
| • | US (toll-free): 1-877-344-7529 |
| • | International: 1-412-317-0088 |
| • | Canada (toll-free): 1-855-669-9658 |
The replay will also be available via online webcast on the Investor Relations section of the Alere website.
Additionally, reconciliations to non-GAAP financial measures not included in this press release that may be discussed during the call will also be available on the Investor Relations section of the Alere website.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, forward-looking statements include statements regarding: the Company expects both Africa and Asia to contribute to near-term growth, tender awards in Africa and Asia will ramp, revenue will rebound in the fourth quarter of 2015, the Company is re-doubling efforts to establish solid and sustainable organic growth, the strength of the Company’s core platforms will eclipse near-term challenges and accelerate overall growth which will enable the Company to deliver enhanced value for our stockholders, expected net revenues for the year ending December 31, 2015, expected non-GAAP adjusted net income from continuing operations available to common stockholders per diluted share for the year ending December 31, 2015, future operating results, and future financial and operational goals. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “intend,” “expect,” “plan,” “believe,” “estimate,” “outlook,” “predict” or the like. These statements involve risks and uncertainties, and actual results could differ materially from the statements made in this press release. Factors that might cause these differences include, but are not limited to: limited demand for certain of our products in the markets we serve; limited market acceptance for new products brought to market (and inability to recover investments made in such products); the effect of intense competition in the markets we serve; ability to execute on business plans; risks and expenses arising from FDA inspections and government subpoenas; delays in product development; international business risks; fluctuations in currency exchange rates; the effects of healthcare reform; risks of clinical trials; potential regulatory burdens and obstacles; litigation and legal compliance risks; government investigations; cybersecurity risks; changes in global economic and political conditions; potential product defects; manufacturing or supply issues; potential intellectual property infringement and risks (and expense) related to the ability to enforce intellectual property rights held by the Company; risks of acquisitions and divestitures; substantial indebtedness and risks related to the inability to refinance outstanding indebtedness;
Page 4 of 5
contractual debt restrictions and requirements; fluctuations in quarterly results; potential future financial restatements; potential reviews, investigations or other proceedings by government authorities, stockholders or other parties; the risk that the Company’s remediation plan related to its material weakness will be unsuccessful to prevent or detect additional misstatements, including a potential inability to prepare financial statements or file periodic reports on a timely basis, which would be a default under the Company’s senior secured credit facility and note indentures as well as a violation of the Securities Exchange Act and the listing rules of the NYSE; and any additional material weaknesses in internal controls. These and other risk factors are discussed in more detail under the heading “Risk Factors” in Item 1A of the Company’s Annual Report on Form 10-K, as amended, filed with the Securities and Exchange Commission on May 28, 2015. Copies are available through the Company’s Investor Relations department and atwww.alere.com. The Company does not assume any obligation to update its forward-looking statements to reflect new information and developments.
About Alere
Alere believes that when diagnosing and monitoring health conditions,Knowing now matters.™ Alere delivers reliable and actionable information by providing rapid diagnostic tests, enhancing clinical and economic healthcare outcomes globally. Headquartered in Waltham, Mass., Alere focuses on rapid diagnostics for cardiometabolic disease, infectious disease and toxicology. For more information on Alere, please visitwww.alere.com.
# # #
Investor Relations
Juliet Cunningham
Vice President, Investor Relations
ir@alere.com
858.805.2232
Page 5 of 5
Alere Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
(in thousands, except per share amounts)
| Three Months Ended September 30, | ||||||||
| 2015 | 2014 | |||||||
Net product sales and services revenue | $ | 598,745 | $ | 645,028 | ||||
License and royalty revenue | 3,299 | 4,182 | ||||||
|
|
|
| |||||
Net revenue | 602,044 | 649,210 | ||||||
Cost of net revenue | 326,995 | 347,588 | ||||||
|
|
|
| |||||
Gross profit | 275,049 | 301,622 | ||||||
Gross margin | 46 | % | 46 | % | ||||
Operating expenses: | ||||||||
Research and development | 36,011 | 38,726 | ||||||
Selling, general and administrative | 207,799 | 227,554 | ||||||
Impairment and loss on disposition, net | 2,074 | — | ||||||
|
|
|
| |||||
Operating income | 29,165 | 35,342 | ||||||
Interest and other income (expense), net | (47,588 | ) | (60,419 | ) | ||||
|
|
|
| |||||
Loss from continuing operations before provision (benefit) for income taxes | (18,423 | ) | (25,077 | ) | ||||
Provision (Benefit) for income taxes | (18,924 | ) | 65,489 | |||||
|
|
|
| |||||
Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax | 501 | (90,566 | ) | |||||
Equity earnings of unconsolidated entities, net of tax | 5,000 | 6,277 | ||||||
|
|
|
| |||||
Income (loss) from continuing operations | 5,501 | (84,289 | ) | |||||
Loss from discontinued operations, net of tax | — | (14,401 | ) | |||||
|
|
|
| |||||
Net income (loss) | 5,501 | (98,690 | ) | |||||
Less: Net loss attributable to non-controlling interests | (61 | ) | (306 | ) | ||||
|
|
|
| |||||
Net income (loss) attributable to Alere Inc. and Subsidiaries | 5,562 | (98,384 | ) | |||||
Preferred stock dividends | (5,367 | ) | (5,367 | ) | ||||
|
|
|
| |||||
Net income (loss) available to common stockholders | $ | 195 | $ | (103,751 | ) | |||
|
|
|
| |||||
Basic net loss per common share: | ||||||||
Loss from continuing operations | $ | — | $ | (1.08 | ) | |||
Loss from discontinued operations | — | (0.17 | ) | |||||
|
|
|
| |||||
Basic net loss per common share | $ | — | $ | (1.25 | ) | |||
|
|
|
| |||||
Diluted net loss per common share: | ||||||||
Loss from continuing operations | $ | — | $ | (1.08 | ) | |||
Loss from discontinued operations | — | (0.17 | ) | |||||
|
|
|
| |||||
Diluted net loss per common share | $ | — | $ | (1.25 | ) | |||
|
|
|
| |||||
Weighted average shares - basic | 85,895 | 83,115 | ||||||
|
|
|
| |||||
Weighted average shares - diluted | 87,169 | 83,115 | ||||||
|
|
|
| |||||
Alere Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
(in thousands, except per share amounts)
| Nine Months Ended September 30, | ||||||||
| 2015 | 2014 | |||||||
Net product sales and services revenue | $ | 1,825,662 | $ | 1,905,849 | ||||
License and royalty revenue | 13,691 | 15,998 | ||||||
|
|
|
| |||||
Net revenue | 1,839,353 | 1,921,847 | ||||||
Cost of net revenue | 979,745 | 1,011,174 | ||||||
|
|
|
| |||||
Gross profit | 859,608 | 910,673 | ||||||
Gross margin | 47 | % | 47 | % | ||||
Operating expenses: | ||||||||
Research and development | 91,225 | 114,855 | ||||||
Selling, general and administrative | 577,566 | 730,591 | ||||||
Impairment and loss on disposition, net | 42,408 | 638 | ||||||
|
|
|
| |||||
Operating income | 148,409 | 64,589 | ||||||
Interest and other income (expense), net | (150,523 | ) | (154,112 | ) | ||||
|
|
|
| |||||
Loss from continuing operations before provision (benefit) for income taxes | (2,114 | ) | (89,523 | ) | ||||
Provision (benefit) for income taxes | (10,009 | ) | 69,273 | |||||
|
|
|
| |||||
Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax | 7,895 | (158,796 | ) | |||||
Equity earnings of unconsolidated entities, net of tax | 10,320 | 13,716 | ||||||
|
|
|
| |||||
Income (loss) from continuing operations | 18,215 | (145,080 | ) | |||||
Income (loss) from discontinued operations, net of taxes | 216,777 | (4,082 | ) | |||||
|
|
|
| |||||
Net income (loss) | 234,992 | (149,162 | ) | |||||
Less: Net income (loss) attributable to non-controlling interests | 386 | (136 | ) | |||||
|
|
|
| |||||
Net income (loss) attributable to Alere Inc. and Subsidiaries | 234,606 | (149,026 | ) | |||||
Preferred stock dividends | (15,926 | ) | (15,926 | ) | ||||
|
|
|
| |||||
Net Income (loss) available to common stockholders | $ | 218,680 | $ | (164,952 | ) | |||
|
|
|
| |||||
Basic net income (loss) per common share: | ||||||||
(Income) loss from continuing operations | $ | 0.02 | $ | (1.94 | ) | |||
Income (loss) from discontinued operations | 2.55 | (0.05 | ) | |||||
|
|
|
| |||||
Net Income (loss) per common share | $ | 2.57 | $ | (1.99 | ) | |||
|
|
|
| |||||
Diluted net income (loss) per common share: | ||||||||
Income (loss) from continuing operations | $ | 0.02 | $ | (1.94 | ) | |||
Income (loss) from discontinued operations | 2.51 | (0.05 | ) | |||||
|
|
|
| |||||
Diluted net income (loss) per common share | $ | 2.53 | $ | (1.99 | ) | |||
|
|
|
| |||||
Weighted average shares - basic | 85,141 | 82,719 | ||||||
|
|
|
| |||||
Weighted average shares - diluted | 86,279 | 82,719 | ||||||
|
|
|
| |||||
Alere Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(in thousands)
| September 30, | December 31, | |||||||
| 2015 | 2014 | |||||||
ASSETS | ||||||||
CURRENT ASSETS: | ||||||||
Cash and cash equivalents | $ | 479,381 | $ | 378,461 | ||||
Restricted cash | 430,821 | 37,571 | ||||||
Marketable securities | 157 | 259 | ||||||
Accounts receivable, net | 452,366 | 466,106 | ||||||
Inventories, net | 362,226 | 365,165 | ||||||
Prepaid expenses and other current assets | 136,447 | 244,986 | ||||||
Assets held for sale | 25,312 | 315,515 | ||||||
|
|
|
| |||||
Total current assets | 1,886,710 | 1,808,063 | ||||||
PROPERTY, PLANT AND EQUIPMENT, NET | 445,315 | 453,570 | ||||||
GOODWILL AND OTHER INTANGIBLE ASSETS, NET | 3,924,614 | 4,246,761 | ||||||
RESTRICTED CASH - NON-CURRENT | 44,148 | — | ||||||
DEFERRED FINANCING COSTS AND OTHER ASSETS, NET | 147,330 | 170,562 | ||||||
Assets held for sale - non-current | 126,048 | — | ||||||
|
|
|
| |||||
Total assets | $ | 6,574,165 | $ | 6,678,956 | ||||
|
|
|
| |||||
LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
CURRENT LIABILITIES: | ||||||||
Short-term debt and current portions of long-term debt and capital lease obligations | $ | 607,597 | $ | 93,116 | ||||
Liabilities related to assets held for sale | 8,836 | 78,843 | ||||||
Other current liabilities | 509,582 | 589,086 | ||||||
|
|
|
| |||||
Total current liabilities | 1,126,015 | 761,045 | ||||||
|
|
|
| |||||
LONG-TERM LIABILITIES: | ||||||||
Long-term debt and capital lease obligations, net of current portions | 2,993,928 | 3,631,945 | ||||||
Deferred tax liabilities | 207,451 | 214,639 | ||||||
Other long-term liabilities | 135,200 | 161,582 | ||||||
Liabilities related to assets held for sale - non-current | 9,603 | — | ||||||
|
|
|
| |||||
Total long-term liabilities | 3,346,182 | 4,008,166 | ||||||
|
|
|
| |||||
TOTAL EQUITY | 2,101,968 | 1,909,745 | ||||||
|
|
|
| |||||
Total liabilities and equity | $ | 6,574,165 | $ | 6,678,956 | ||||
|
|
|
| |||||
Alere Inc. and Subsidiaries
Reconciliation to Non-GAAP Adjusted Operating Results
(in thousands, except per share amounts)
| Three Months Ended September 30, | ||||||||
| 2015 | 2014 | |||||||
Reconciliation to Non-GAAP Adjusted Operating Income(1) | ||||||||
Operating income | $ | 29,165 | $ | 35,342 | ||||
Adjustment related to acquired software license contracts | 430 | 324 | ||||||
Amortization of acquisition-related intangible assets | 60,928 | 58,813 | ||||||
Restructuring charges | 2,264 | 17,296 | ||||||
Stock-based compensation expense | 7,317 | 3,168 | ||||||
Compensation charges associated with acquisition-related contingent consideration obligations | 191 | 670 | ||||||
Acquisition-related costs | 241 | 325 | ||||||
Fair value adjustments to acquisition-related contingent consideration | 957 | (5,537 | ) | |||||
Costs associated with potential business dispositions | 1,878 | 6,203 | ||||||
Impairment and loss on disposition, net | 2,074 | — | ||||||
|
|
|
| |||||
Non-GAAP adjusted operating income | $ | 105,445 | $ | 116,604 | ||||
|
|
|
| |||||
| Three Months Ended September 30, | ||||||||
| 2015 | 2014 | |||||||
Reconciliation to Non-GAAP Adjusted Net Income (1) | ||||||||
Net income (loss) available to common stockholders | $ | 195 | $ | (103,751 | ) | |||
Adjustment related to acquired software license contracts | 430 | 324 | ||||||
Amortization of acquisition-related intangible assets | 60,954 | 58,818 | ||||||
Restructuring charges | 2,270 | 17,307 | ||||||
Stock-based compensation expense | 7,317 | 3,168 | ||||||
Compensation charges associated with acquisition-related contingent consideration obligations | 191 | 670 | ||||||
Acquisition-related costs | 241 | 325 | ||||||
Fair value adjustments to acquisition-related contingent consideration | 957 | (5,537 | ) | |||||
Costs associated with potential business dispositions | 1,878 | 6,203 | ||||||
Impairment and loss on disposition, net | 2,074 | — | ||||||
Loss on sale of equity investment | — | 457 | ||||||
Write off of equity investment in BBI | 662 | — | ||||||
Interest expense recorded in connection with fees paid for certain debt modifications and the termination of our senior secured credit facility | 9,273 | 363 | ||||||
Interest accretion associated with acquisition-related compensation charges | 35 | 102 | ||||||
Amortization of acquisition-related intangible assets, restructuring, fair value adjustments to acquisition-related contingent consideration, and impairment, net of gain on divestiture - Discontinued operations, net of tax | — | 17,223 | ||||||
Income tax effects on items above | (38,179 | ) | 37,139 | |||||
|
|
|
| |||||
Non-GAAP adjusted net income available to common stockholders | $ | 48,298 | $ | 32,811 | ||||
|
|
|
| |||||
Loss per diluted common share from continuing operations | $ | — | $ | (1.08 | ) | |||
Loss per diluted common share from discontinued operations | — | (0.17 | ) | |||||
|
|
|
| |||||
Net loss per diluted common share | $ | — | $ | (1.25 | ) | |||
|
|
|
| |||||
Weighted average shares - diluted | 87,169 | 83,115 | ||||||
|
|
|
| |||||
Non-GAAP adjusted income per diluted common share from continuing operations(2) | $ | 0.54 | $ | 0.35 | ||||
Non-GAAP adjusted income per diluted common share from discontinued operations(2) | — | 0.03 | ||||||
|
|
|
| |||||
Non-GAAP adjusted net income per diluted common share (2) | $ | 0.54 | $ | 0.38 | ||||
|
|
|
| |||||
Non-GAAP adjusted weighted average shares - diluted(2) | 100,846 | 87,929 | ||||||
|
|
|
| |||||
| (1) | In calculating “Non-GAAP adjusted operating income” and “Non-GAAP adjusted net income available to common stockholders”, the Company excludes (i) certain non-cash charges, including amortization expense and stock-based compensation expense, (ii) non-recurring charges and income, and (iii) certain other charges and income that have a significant positive or negative impact on results yet do not occur on a consistent or regular basis in its business. In determining whether a particular item meets one of these criteria, management considers facts and circumstances that it believes are relevant. Management believes that excluding such charges and income from operating income and net income or loss allows investors and management to evaluate and compare the Company’s operating results from continuing operations from period to period in a meaningful and consistent manner. Due to the frequency of their occurrence in its business, the Company does not adjust operating income or net income or loss for the costs associated with litigation, including payments made or received through settlements. It should be noted that “Non-GAAP adjusted operating income” and “Non-GAAP adjusted net income available to common stockholders” are not standard financial measurements under accounting principles generally accepted in the United States of America (“GAAP”) and should not be considered as an alternative to operating income and net income or loss or cash flow from operating activities, as a measure of liquidity or as an indicator of operating performance or any measure of performance derived in accordance with GAAP. In addition, all companies do not calculate non-GAAP financial measures in the same manner and, accordingly, “Non-GAAP adjusted operating income” and “Non-GAAP adjusted net income available to common stockholders” presented in this press release may not be comparable to similar measures used by other companies. |
| (2) | Included in the weighted average diluted common shares for the calculation of net income per common share for the three months ended September 30, 2015, on a non-GAAP adjusted basis, are dilutive shares consisting of 1,244,000 common stock equivalent shares from the potential exercise of stock options and warrants. Also included were dilutive shares consisting of 3,438,000 common stock equivalent shares from the potential conversion of convertible debt securities, 30,000 potentially issuable shares of common stock associated with a contingent consideration arrangement, and 10,239,000 common stock equivalent shares from the potential conversion of Series B convertible preferred stock. The diluted net income per common share calculation for the three months ended September 30, 2015, on a non-GAAP adjusted basis, included the add back of interest expense related to the convertible debt of $0.7 million and the add back of $5.4 million of preferred stock dividends related to the Series B convertible preferred stock, resulting in net income available to common stockholders of $54.4 million for the three months ended September 30, 2015. |
Included in the weighted average diluted common shares for the calculation of net income per common share for the three months ended September 30, 2014, on a non-GAAP adjusted basis, were dilutive shares consisting of 1,376,000 common stock equivalent shares from the potential exercise of stock options and warrants. Also included were potential dilutive shares consisting of 3,438,000 common stock equivalent shares from the potential conversion of convertible debt securities. The diluted net income per common share calculation for the three months ended September 30, 2014, on a non-GAAP adjusted basis, included the add back of interest expense related to the convertible debt of $0.7 million, resulting in net income available to common stockholders of $33.5 million for the three months ended September 30, 2014.
Alere Inc. and Subsidiaries
Reconciliation to Non-GAAP Adjusted Operating Results
(in thousands, except per share amounts)
| Nine Months Ended September 30, | ||||||||
| 2015 | 2014 | |||||||
Reconciliation to Non-GAAP Adjusted Operating Income(1) | ||||||||
Operating income | $ | 148,409 | $ | 64,589 | ||||
Adjustment related to acquired software license contracts | 877 | 1,116 | ||||||
Amortization of acquisition-related intangible assets | 160,867 | 176,608 | ||||||
Restructuring charges | 11,387 | 37,074 | ||||||
Stock-based compensation expense | 19,596 | 7,750 | ||||||
Compensation charges associated with acquisition-related contingent consideration obligations | (2,615 | ) | 1,673 | |||||
Acquisition-related costs | 332 | 695 | ||||||
Fair value adjustments to acquisition-related contingent consideration | (51,910 | ) | 12,442 | |||||
Non-cash charge associated with acquired inventory | — | — | ||||||
Costs associated with potential business dispositions | 6,097 | 20,763 | ||||||
Impairment and loss on disposition, net | 42,408 | 638 | ||||||
|
|
|
| |||||
Non-GAAP adjusted operating income | $ | 335,448 | $ | 323,348 | ||||
|
|
|
| |||||
| Nine Months Ended September 30, | ||||||||
| 2015 | 2014 | |||||||
Reconciliation to Non-GAAP Adjusted Net Income (1) | ||||||||
Net income (loss) available to common stockholders | $ | 218,680 | $ | (164,952 | ) | |||
Adjustment related to acquired software license contracts | 877 | 1,116 | ||||||
Amortization of acquisition-related intangible assets | 160,941 | 176,651 | ||||||
Restructuring charges | 11,406 | 37,108 | ||||||
Stock-based compensation expense | 19,596 | 7,750 | ||||||
Compensation charges associated with acquisition-related contingent consideration obligations | (2,615 | ) | 1,673 | |||||
Acquisition-related costs | 332 | 695 | ||||||
Fair value adjustments to acquisition-related contingent consideration | (51,910 | ) | 12,442 | |||||
Costs associated with potential business dispositions | 6,488 | 20,763 | ||||||
Impairment and loss on disposition, net | 42,408 | 638 | ||||||
Loss on sale of equity investment | — | 457 | ||||||
Write off of equity investment in BBI | 662 | — | ||||||
Interest expense recorded in connection with fees paid for certain debt modifications and the termination of our senior secured credit facility | 20,940 | 1,091 | ||||||
Interest accretion associated with acquisition-related compensation charges | (406 | ) | 295 | |||||
Expense associated with extinguishment of debt | 3,480 | — | ||||||
Amortization of acquisition-related intangible assets, restructuring, fair value adjustments to acquisition-related contingent consideration, and impairment, net of gain on divestiture - Discontinued operations, net of tax | (217,589 | ) | 12,386 | |||||
Income tax effects on items above | (70,821 | ) | 6,766 | |||||
|
|
|
| |||||
Non-GAAP adjusted net income available to common stockholders | $ | 142,469 | $ | 114,879 | ||||
|
|
|
| |||||
Income (loss) per diluted common share from continuing operations | $ | 0.02 | $ | (1.94 | ) | |||
Income (loss) per diluted common share from discontinued operations | 2.51 | (0.05 | ) | |||||
|
|
|
| |||||
Net income (loss) per diluted common share | $ | 2.53 | $ | (1.99 | ) | |||
|
|
|
| |||||
Weighted average shares - diluted | 86,279 | 82,719 | ||||||
|
|
|
| |||||
Non-GAAP adjusted income per diluted common share from continuing operations(2) | $ | 1.62 | $ | 1.25 | ||||
Non-GAAP adjusted income (loss) per diluted common share from discontinued operations(2) | (0.01 | ) | 0.09 | |||||
|
|
|
| |||||
Non-GAAP adjusted net income per diluted common share (2) | $ | 1.61 | $ | 1.34 | ||||
|
|
|
| |||||
Non-GAAP adjusted weighted average shares - diluted(2) | 99,956 | 87,311 | ||||||
|
|
|
| |||||
| (1) | In calculating “Non-GAAP adjusted operating income” and “Non-GAAP adjusted net income available to common stockholders”, the Company excludes (i) certain non-cash charges, including amortization expense and stock-based compensation expense, (ii) non-recurring charges and income, and (iii) certain other charges and income that have a significant positive or negative impact on results yet do not occur on a consistent or regular basis in its business. In determining whether a particular item meets one of these criteria, management considers facts and circumstances that it believes are relevant. Management believes that excluding such charges and income from operating income and net income or loss allows investors and management to evaluate and compare the Company’s operating results from continuing operations from period to period in a meaningful and consistent manner. Due to the frequency of their occurrence in its business, the Company does not adjust operating income or net income or loss for the costs associated with litigation, including payments made or received through settlements. It should be noted that “Non-GAAP adjusted operating income” and “Non-GAAP adjusted net income available to common stockholders” are not standard financial measurements under accounting principles generally accepted in the United States of America (“GAAP”) and should not be considered as an alternative to operating income and net income or loss or cash flow from operating activities, as a measure of liquidity or as an indicator of operating performance or any measure of performance derived in accordance with GAAP. In addition, all companies do not calculate non-GAAP financial measures in the same manner and, accordingly, “Non-GAAP adjusted operating income” and “Non-GAAP adjusted net income available to common stockholders” presented in this press release may not be comparable to similar measures used by other companies. |
| (2) | Included in the weighted average diluted common shares for the calculation of net income per common share for the nine months ended September 30, 2015, on a non-GAAP adjusted basis, are dilutive shares consisting of 1,120,000 common stock equivalent shares from the potential exercise of stock options and warrants. Also included were dilutive shares consisting of 3,438,000 common stock equivalent shares from the potential conversion of convertible debt securities, 18,000 potentially issuable shares of common stock associated with a contingent consideration arrangement, and 10,239,000 common stock equivalent shares from the potential conversion of Series B convertible preferred stock. The diluted net income per common share calculation for the nine months ended September 30, 2015, on a non-GAAP adjusted basis, included the add back of interest expense related to the convertible debt of $2.1 million and the add back of $15.9 million of preferred stock dividends related to the Series B convertible preferred stock, resulting in net income available to common stockholders of $160.5 million for the nine months ended September 30, 2015. |
Included in the weighted average diluted common shares for the calculation of net income per common share for the nine months ended September 30, 2014, on a non-GAAP adjusted basis, were dilutive shares consisting of 1,154,000 common stock equivalent shares from the potential exercise of stock options and warrants. Also included were potential dilutive shares consisting of 3,438,000 common stock equivalent shares from the potential conversion of convertible debt securities. The diluted net income per common share calculation for the nine months ended September 30, 2014, on a non-GAAP adjusted basis, included the add back of interest expense related to the convertible debt of $2.2 million, resulting in net income available to common stockholders of $117.1 million for the nine months ended September 30, 2014.
Alere Inc. and Subsidiaries
Selected Consolidated Revenues
(in thousands)
| Q3 2015 | YTD 2015 | Q3 2014 | YTD 2014 | % Change Q3 15 v. Q3 14 | % Change YTD 15 v. YTD 14 | |||||||||||||||||||
Professional diagnostics segment(1) | ||||||||||||||||||||||||
Cardiometabolic | $ | 208,319 | $ | 624,823 | $ | 208,248 | $ | 631,452 | 0 | % | -1 | % | ||||||||||||
Infectious disease | 163,759 | 519,145 | 184,018 | 526,632 | -11 | % | -1 | % | ||||||||||||||||
Toxicology | 162,571 | 468,822 | 166,381 | 491,561 | -2 | % | -5 | % | ||||||||||||||||
Other(2) | 45,349 | 147,512 | 65,183 | 190,986 | -30 | % | -23 | % | ||||||||||||||||
|
|
|
|
|
|
|
| |||||||||||||||||
Total professional diagnostics | 579,998 | 1,760,302 | 623,830 | 1,840,631 | -7 | % | -4 | % | ||||||||||||||||
Consumer diagnostics segment(1) | 18,747 | 65,360 | 21,198 | 65,218 | -12 | % | 0 | % | ||||||||||||||||
License and royalty revenue | 3,299 | 13,691 | 4,182 | 15,998 | -21 | % | -14 | % | ||||||||||||||||
|
|
|
|
|
|
|
| |||||||||||||||||
Net revenue | $ | 602,044 | $ | 1,839,353 | $ | 649,210 | $ | 1,921,847 | -7 | % | -4 | % | ||||||||||||
|
|
|
|
|
|
|
| |||||||||||||||||
| (1) | Revenues have been restated for the impact of a change in segment reporting due to the divestiture of our health management business. |
| (2) | Revenues are presented in accordance with generally accepted accounting principles and exclude an adjustment of $0.5 million and $0.9 million, and $0.3 million and $1.1 million related to acquired software license contracts which were not recognized during the three and nine months ended September 30, 2015 and 2014, respectively, due to business combination accounting rules. |
Alere Inc. and Subsidiaries
Reconciliation of Operating Income (Loss) to Non-GAAP Adjusted Operating Income (Loss)
(in thousands)
| For the Three Months Ended September 30, 2015 | ||||||||||||||||
| Professional Diagnostics | Consumer Diagnostics | Corporate | Total | |||||||||||||
Operating Segment | ||||||||||||||||
Net revenue | $ | 583,297 | $ | 18,747 | $ | — | $ | 602,044 | ||||||||
Adjustment related to acquired software license contracts (1) | 430 | — | — | 430 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
Non-GAAP adjusted net revenue | $ | 583,727 | $ | 18,747 | $ | — | $ | 602,474 | ||||||||
|
|
|
|
|
|
|
| |||||||||
Operating income (loss) | $ | 54,450 | $ | 1,039 | $ | (26,324 | ) | $ | 29,165 | |||||||
Adjustment related to acquired software license contracts (1) | 430 | — | — | 430 | ||||||||||||
Amortization of acquisition-related intangible assets | 60,880 | 9 | 39 | 60,928 | ||||||||||||
Restructuring charges | 1,578 | — | 686 | 2,264 | ||||||||||||
Stock-based compensation expense | — | — | 7,317 | 7,317 | ||||||||||||
Compensation charges associated with acquisition-related contingent consideration obligations | 191 | — | — | 191 | ||||||||||||
Acquisition-related costs | — | — | 241 | 241 | ||||||||||||
Fair value adjustments to acquisition-related contingent consideration | 957 | — | — | 957 | ||||||||||||
Costs associated with potential business dispositions | 1,878 | — | — | 1,878 | ||||||||||||
Impairment and loss on disposition, net | 2,074 | — | — | 2,074 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
Non-GAAP adjusted operating income (loss) | $ | 122,438 | $ | 1,048 | $ | (18,041 | ) | $ | 105,445 | |||||||
|
|
|
|
|
|
|
| |||||||||
Non-GAAP adjusted operating income (loss) as % of Non-GAAP adjusted net revenue | 21.0 | % | 5.6 | % | 17.5 | % | ||||||||||
|
|
|
|
|
| |||||||||||
| (1) | Estimated revenue related to acquired software license contracts that was not recognized during the three months ended September 30, 2015 due to business combination accounting rules. |
| For the Three Months Ended September 30, 2014 | ||||||||||||||||
| Professional Diagnostics | Consumer Diagnostics | Corporate | Total | |||||||||||||
Operating Segment | ||||||||||||||||
Net revenue(1) | $ | 628,012 | $ | 21,198 | $ | — | $ | 649,210 | ||||||||
Adjustment related to acquired software license contracts (2) | 324 | — | — | 324 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
Non-GAAP adjusted net revenue | $ | 628,336 | $ | 21,198 | $ | — | $ | 649,534 | ||||||||
|
|
|
|
|
|
|
| |||||||||
Operating income (loss) | $ | 67,232 | $ | 1,499 | $ | (33,389 | ) | $ | 35,342 | |||||||
Adjustment related to acquired software license contracts (2) | 324 | — | — | 324 | ||||||||||||
Amortization of acquisition-related intangible assets | 57,306 | 175 | 1,332 | 58,813 | ||||||||||||
Restructuring charges | 14,118 | — | 3,178 | 17,296 | ||||||||||||
Stock-based compensation expense | — | — | 3,168 | 3,168 | ||||||||||||
Compensation charges associated with acquisition-related contingent consideration obligations | 670 | — | — | 670 | ||||||||||||
Acquisition-related costs | — | — | 325 | 325 | ||||||||||||
Fair value adjustments to acquisition-related contingent consideration | (8,637 | ) | — | 3,100 | (5,537 | ) | ||||||||||
Costs associated with potential business dispositions | 6,203 | — | — | 6,203 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
Non-GAAP adjusted operating income (loss) | $ | 137,216 | $ | 1,674 | $ | (22,286 | ) | $ | 116,604 | |||||||
|
|
|
|
|
|
|
| |||||||||
Non-GAAP adjusted operating income (loss) as % of Non-GAAP adjusted net revenue | 21.8 | % | 7.9 | % | 18.0 | % | ||||||||||
|
|
|
|
|
| |||||||||||
| (1) | Net revenue has been restated for the impact of a change in segment reporting due to the divestiture of our health management business. |
| (2) | Estimated revenue related to acquired software license contracts that was not recognized during the three months ended September 30, 2014 due to business combination accounting rules. |
Comments:
In calculating “Non-GAAP adjusted operating income (loss)” in the schedule presented above, the Company excludes from “Operating income (loss)” (i) certain non-cash charges, including amortization expense and stock-based compensation expense, (ii) non-recurring charges and income, and (iii) certain other charges and income that have a significant positive or negative impact on results yet do not occur on a consistent or regular basis in its business. In determining whether a particular item meets one of these criteria, management considers facts and circumstances that it believes are relevant. Management believes that excluding such charges and income from “Operating income (loss)” allows investors and management to evaluate and compare the Company’s operating results from continuing operations from period to period in a meaningful and consistent manner. Due to the frequency of their occurrence in its business, the Company does not adjust “Operating income (loss)” for the costs associated with litigation, including payments made or received through settlements. It should be noted that “Non-GAAP adjusted operating income (loss)” is not a standard financial measurement under accounting principles generally accepted in the United States of America (“GAAP”) and should not be considered as an alternative to “Operating income (loss)” as an indicator of operating performance or any measure of performance derived in accordance with GAAP. In addition, all companies do not calculate non-GAAP financial measures in the same manner and, accordingly, “Non-GAAP adjusted operating income (loss)” presented in this schedule may not be comparable to similar measures used by other companies.
Reference should also be made to the Company’s financial results contained in our earnings press release respective to the periods presented in this schedule, which include a more detailed discussion of the adjustments to the GAAP operating results presented above.
Alere Inc. and Subsidiaries
Reconciliation of Operating Income (Loss) to Non-GAAP Adjusted Operating Income (Loss)
(in thousands)
| For the Nine Months Ended September 30, 2015 | ||||||||||||||||
| Professional Diagnostics | Consumer Diagnostics | Corporate | Total | |||||||||||||
Operating Segment | ||||||||||||||||
Net revenue | $ | 1,773,993 | $ | 65,360 | $ | — | $ | 1,839,353 | ||||||||
Adjustment related to acquired software license contracts (1) | 877 | — | — | 877 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
Non-GAAP adjusted net revenue | $ | 1,774,870 | $ | 65,360 | $ | — | $ | 1,840,230 | ||||||||
|
|
|
|
|
|
|
| |||||||||
Operating income (loss) | $ | 219,543 | $ | 4,322 | $ | (75,456 | ) | $ | 148,409 | |||||||
Adjustment related to acquired software license contracts (1) | 877 | — | — | 877 | ||||||||||||
Amortization of acquisition-related intangible assets | 160,723 | 28 | 116 | 160,867 | ||||||||||||
Restructuring charges | 10,103 | — | 1,284 | 11,387 | ||||||||||||
Stock-based compensation expense | — | — | 19,596 | 19,596 | ||||||||||||
Compensation charges associated with acquisition-related contingent consideration obligations | (2,615 | ) | — | — | (2,615 | ) | ||||||||||
Acquisition-related costs | — | — | 332 | 332 | ||||||||||||
Fair value adjustments to acquisition-related contingent consideration | — | — | (51,910 | ) | (51,910 | ) | ||||||||||
Costs associated with potential business dispositions | 6,488 | — | — | 6,488 | ||||||||||||
Impairment and gain (loss) on dispositions, net | 42,408 | — | — | 42,408 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
Non-GAAP adjusted operating income (loss) | $ | 437,527 | $ | 4,350 | $ | (106,038 | ) | $ | 335,839 | |||||||
|
|
|
|
|
|
|
| |||||||||
Non-GAAP adjusted operating income (loss) as % of Non-GAAP adjusted net revenue | 24.7 | % | 6.7 | % | 18.2 | % | ||||||||||
|
|
|
|
|
| |||||||||||
| (1) | Estimated revenue related to acquired software license contracts that was not recognized during the nine months ended September 30, 2015 due to business combination accounting rules. |
| For the Nine Months Ended September 30, 2014 | ||||||||||||||||
| Professional Diagnostics | Consumer Diagnostics | Corporate | Total | |||||||||||||
Operating Segment | ||||||||||||||||
Net revenue(1) | $ | 1,855,318 | $ | 66,529 | $ | — | $ | 1,921,847 | ||||||||
Adjustment related to acquired software license contracts (2) | 1,116 | — | — | 1,116 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
Non-GAAP adjusted net revenue | $ | 1,856,434 | $ | 66,529 | $ | — | $ | 1,922,963 | ||||||||
|
|
|
|
|
|
|
| |||||||||
Operating income (loss) | $ | 135,856 | $ | 4,210 | $ | (75,477 | ) | $ | 64,589 | |||||||
Adjustment related to acquired software license contracts (2) | 1,116 | — | — | 1,116 | ||||||||||||
Amortization of acquisition-related intangible assets | 174,638 | 638 | 1,332 | 176,608 | ||||||||||||
Restructuring charges | 29,746 | — | 7,328 | 37,074 | ||||||||||||
Stock-based compensation expense | — | — | 7,750 | 7,750 | ||||||||||||
Compensation charges associated with acquisition-related contingent consideration obligations | 1,673 | — | — | 1,673 | ||||||||||||
Acquisition-related costs | — | — | 695 | 695 | ||||||||||||
Fair value adjustments to acquisition-related contingent consideration | 9,042 | — | 3,400 | 12,442 | ||||||||||||
Costs associated with potential business dispositions | 20,763 | — | — | 20,763 | ||||||||||||
Loss on disposition | 638 | — | — | 638 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
Non-GAAP adjusted operating income (loss) | $ | 373,472 | $ | 4,848 | $ | (54,972 | ) | $ | 323,348 | |||||||
|
|
|
|
|
|
|
| |||||||||
Non-GAAP adjusted operating income (loss) as % of Non-GAAP adjusted net revenue | 20.1 | % | 7.3 | % | 16.8 | % | ||||||||||
|
|
|
|
|
| |||||||||||
| (1) | Net revenue has been restated for the impact of a change in segment reporting due to the divestiture of our health management business. |
| (2) | Estimated revenue related to acquired software license contracts that was not recognized during the nine months ended September 30, 2014 due to business combination accounting rules. |
Comments:
In calculating “Non-GAAP adjusted operating income (loss)” in the schedule presented above, the Company excludes from “Operating income (loss)” (i) certain non-cash charges, including amortization expense and stock-based compensation expense, (ii) non-recurring charges and income, and (iii) certain other charges and income that have a significant positive or negative impact on results yet do not occur on a consistent or regular basis in its business. In determining whether a particular item meets one of these criteria, management considers facts and circumstances that it believes are relevant. Management believes that excluding such charges and income from “Operating income (loss)” allows investors and management to evaluate and compare the Company’s operating results from continuing operations from period to period in a meaningful and consistent manner. Due to the frequency of their occurrence in its business, the Company does not adjust “Operating income (loss)” for the costs associated with litigation, including payments made or received through settlements. It should be noted that “Non-GAAP adjusted operating income (loss)” is not a standard financial measurement under accounting principles generally accepted in the United States of America (“GAAP”) and should not be considered as an alternative to “Operating income (loss)” as an indicator of operating performance or any measure of performance derived in accordance with GAAP. In addition, all companies do not calculate non-GAAP financial measures in the same manner and, accordingly, “Non-GAAP adjusted operating income (loss)” presented in this schedule may not be comparable to similar measures used by other companies.
Reference should also be made to the Company’s financial results contained in our earnings press release respective to the periods presented in this schedule, which include a more detailed discussion of the adjustments to the GAAP operating results presented above.
Alere Inc. and Subsidiaries
Reconciliations to Non-GAAP Adjusted P&L Categories
(in thousands)
| Three Months Ended September 30, 2015 | Three Months Ended September 30, 2014 | |||||||
Net revenue | $ | 602,044 | $ | 649,210 | ||||
Adjustment related to acquired software license contracts | 430 | 324 | ||||||
|
|
|
| |||||
Non-GAAP adjusted net revenue (1) | $ | 602,474 | $ | 649,534 | ||||
|
|
|
| |||||
Cost of net revenue | $ | 326,995 | $ | 347,588 | ||||
Less adjustments: | ||||||||
Amortization of acquisition-related intangible assets | (16,132 | ) | (15,684 | ) | ||||
Restructuring charges | (523 | ) | (5,654 | ) | ||||
Stock-based compensation expense | (326 | ) | (291 | ) | ||||
|
|
|
| |||||
Non-GAAP adjusted cost of net revenue (1) | $ | 310,014 | $ | 325,959 | ||||
|
|
|
| |||||
Non-GAAP adjusted gross profit (1) | $ | 292,460 | $ | 323,575 | ||||
|
|
|
| |||||
| Three Months Ended September 30, 2015 | Three Months Ended September 30, 2014 | |||||||
Research and development | $ | 36,011 | $ | 38,726 | ||||
Less adjustments: | ||||||||
Amortization of acquisition-related intangible assets | (8,304 | ) | (1,372 | ) | ||||
Restructuring charges | (18 | ) | (5,457 | ) | ||||
Stock-based compensation expense | (287 | ) | (279 | ) | ||||
|
|
|
| |||||
Non-GAAP adjusted research and development (1) | $ | 27,402 | $ | 31,618 | ||||
|
|
|
| |||||
| Three Months Ended September 30, 2015 | Three Months Ended September 30, 2014 | |||||||
Selling, general and administrative | $ | 207,799 | $ | 227,554 | ||||
Less adjustments: | ||||||||
Amortization of acquisition-related intangible assets | (36,492 | ) | (41,757 | ) | ||||
Restructuring charges | (1,723 | ) | (6,185 | ) | ||||
Stock-based compensation expense | (6,704 | ) | (2,598 | ) | ||||
Compensation charges associated with acquisition-related contingent consideration obligations | (191 | ) | (670 | ) | ||||
Acquisition-related costs | (241 | ) | (325 | ) | ||||
Fair value adjustments to acquisition-related contingent consideration | (957 | ) | 5,537 | |||||
Costs associated with potential business dispositions | (1,878 | ) | (6,203 | ) | ||||
|
|
|
| |||||
Non-GAAP adjusted selling, general and administrative(1) | $ | 159,613 | $ | 175,353 | ||||
|
|
|
| |||||
| Three Months Ended September 30, 2015 | Three Months Ended September 30, 2014 | |||||||
Impairment and loss on disposition, net | $ | 2,074 | $ | — | ||||
Impairment and loss on disposition, net | (2,074 | ) | — | |||||
|
|
|
| |||||
Non-GAAP adjusted impairment and loss on disposition, net(1) | $ | — | $ | — | ||||
|
|
|
| |||||
| Three Months Ended September 30, 2015 | Three Months Ended September 30, 2014 | |||||||
Interest and other income (expense), net | $ | (47,588 | ) | $ | (60,419 | ) | ||
Less adjustments: | ||||||||
Restructuring charges | 6 | 11 | ||||||
Write off of equity investment in BBI | 662 | — | ||||||
Interest expense recorded in connection with fees paid for certain debt modifications and the termination of our senior secured credit facility | 9,273 | 363 | ||||||
Interest accretion associated with acquisition-related compensation charges | 35 | 102 | ||||||
|
|
|
| |||||
Non-GAAP adjusted interest and other income (expense), net(1) | $ | (37,612 | ) | $ | (59,943 | ) | ||
|
|
|
| |||||
| Three Months Ended September 30, 2015 | Three Months Ended September 30, 2014 | |||||||
Provision (benefit) for income taxes | $ | (18,924 | ) | $ | 65,489 | |||
Add: Income tax effects on Non-GAAP adjustments | 38,200 | (37,109 | ) | |||||
|
|
|
| |||||
Non-GAAP adjusted provision for income taxes, net(1) | $ | 19,276 | $ | 28,380 | ||||
|
|
|
| |||||
| Three Months Ended September 30, 2015 | Three Months Ended September 30, 2014 | |||||||
Equity earnings of unconsolidated entities, net of tax | $ | 5,000 | $ | 6,277 | ||||
Less adjustments: | ||||||||
Amortization of acquisition-related intangible assets | 104 | 132 | ||||||
Loss on sale of equity investment | — | 457 | ||||||
Income tax effects on items above | — | — | ||||||
|
|
|
| |||||
Non-GAAP adjusted equity earnings of unconsolidated entities, net of tax(1) | $ | 5,104 | $ | 6,866 | ||||
|
|
|
| |||||
| Three Months Ended September 30, 2015 | Three Months Ended September 30, 2014 | |||||||
Loss from discontinued operations, net of taxes | $ | — | $ | (14,401 | ) | |||
Less adjustments: | ||||||||
Amortization of acquisition-related intangible assets | — | 7,514 | ||||||
Restructuring charges | — | 562 | ||||||
Goodwill impairment charge | — | 17,984 | ||||||
Fair value adjustments to acquisition-related contingent consideration | — | (25,071 | ) | |||||
Income tax effects on items above | — | 16,234 | ||||||
|
|
|
| |||||
Non-GAAP adjusted income from discontinued operations, net of taxes(1) | $ | — | $ | 2,822 | ||||
|
|
|
| |||||
| Three Months Ended September 30, 2015 | Three Months Ended September 30, 2014 | |||||||
Net loss attributable to non-controlling interests, net of tax | $ | (61 | ) | $ | (306 | ) | ||
Less: Amortization of acquisition-related intangible assets, net of tax | 78 | 127 | ||||||
Income tax effects on items above | 21 | 30 | ||||||
|
|
|
| |||||
Non-GAAP adjusted net loss attributable to non-controlling interests, net of tax(1) | $ | (4 | ) | $ | (209 | ) | ||
|
|
|
| |||||
(1) The following is a summary of our non-GAAP adjusted measures included above: | ||||||||
Non-GAAP adjusted net revenue | $ | 602,474 | $ | 649,534 | ||||
Non-GAAP adjusted cost of net revenue | $ | 310,014 | $ | 325,959 | ||||
Non-GAAP adjusted research and development | $ | 27,402 | $ | 31,618 | ||||
Non-GAAP adjusted selling, general and administrative | $ | 159,613 | $ | 175,353 | ||||
Non-GAAP adjusted impairment and loss on dispositions, net | $ | — | $ | — | ||||
Non-GAAP adjusted interest and other income (expense), net | $ | (37,612 | ) | $ | (59,943 | ) | ||
Non-GAAP adjusted provision for income taxes | $ | 19,276 | $ | 28,380 | ||||
Non-GAAP adjusted equity earnings of unconsolidated entities, net of tax | $ | 5,104 | $ | 6,866 | ||||
Non-GAAP adjusted income from discontinued operations, net of tax | $ | — | $ | 2,822 | ||||
Non-GAAP adjusted net loss attributable to non-controlling interests, net of tax | $ | (4 | ) | $ | (209 | ) | ||
Alere Inc. and Subsidiaries
Reconciliations to Non-GAAP Adjusted P&L Categories
(in thousands)
| Nine Months Ended September 30, 2015 | Nine Months Ended September 30, 2014 | |||||||
Net revenue | $ | 1,839,353 | $ | 1,921,847 | ||||
Adjustment related to acquired software license contracts | 877 | 1,116 | ||||||
|
|
|
| |||||
Non-GAAP adjusted net revenue (1) | $ | 1,840,230 | $ | 1,922,963 | ||||
|
|
|
| |||||
Cost of net revenue | $ | 979,745 | $ | 1,011,174 | ||||
Less adjustments: | ||||||||
Amortization of acquisition-related intangible assets | (43,440 | ) | (47,242 | ) | ||||
Restructuring charges | (2,921 | ) | (6,707 | ) | ||||
Stock-based compensation expense | (866 | ) | (863 | ) | ||||
Costs associated with potential business dispositions | (391 | ) | — | |||||
|
|
|
| |||||
Non-GAAP adjusted cost of net revenue (1) | $ | 932,127 | $ | 956,362 | ||||
|
|
|
| |||||
Non-GAAP adjusted gross profit (1) | $ | 908,103 | $ | 966,601 | ||||
|
|
|
| |||||
| Nine Months Ended September 30, 2015 | Nine Months Ended September 30, 2014 | |||||||
Research and development | $ | 91,225 | $ | 114,855 | ||||
Less adjustments: | ||||||||
Amortization of acquisition-related intangible assets | (10,088 | ) | (3,721 | ) | ||||
Restructuring charges | (666 | ) | (8,488 | ) | ||||
Stock-based compensation expense | (893 | ) | 341 | |||||
|
|
|
| |||||
Non-GAAP adjusted research and development (1) | $ | 79,578 | $ | 102,987 | ||||
|
|
|
| |||||
| Nine Months Ended September 30, 2015 | Nine Months Ended September 30, 2014 | |||||||
Selling, general and administrative | $ | 577,566 | $ | 730,591 | ||||
Less adjustments: | ||||||||
Amortization of acquisition-related intangible assets | (107,339 | ) | (125,645 | ) | ||||
Restructuring charges | (7,800 | ) | (21,879 | ) | ||||
Stock-based compensation expense | (17,837 | ) | (7,228 | ) | ||||
Compensation charges associated with acquisition-related contingent consideration obligations | 2,615 | (1,673 | ) | |||||
Acquisition-related costs | (332 | ) | (695 | ) | ||||
Fair value adjustments to acquisition-related contingent consideration | 51,910 | (12,442 | ) | |||||
Costs associated with potential business dispositions | (6,097 | ) | (20,763 | ) | ||||
|
|
|
| |||||
Non-GAAP adjusted selling, general and administrative(1) | $ | 492,686 | $ | 540,266 | ||||
|
|
|
| |||||
| Nine Months Ended September 30, 2015 | Nine Months Ended September 30, 2014 | |||||||
Impairment and loss on disposition, net | $ | 42,408 | $ | 638 | ||||
Impairment and loss on disposition, net | (42,408 | ) | (638 | ) | ||||
|
|
|
| |||||
Non-GAAP adjusted impairment and loss on disposition, net(1) | $ | — | $ | — | ||||
|
|
|
| |||||
| Nine Months Ended September 30, 2015 | Nine Months Ended September 30, 2014 | |||||||
Interest and other income (expense), net | $ | (150,523 | ) | $ | (154,112 | ) | ||
Less adjustments: | ||||||||
Restructuring charges | 19 | 34 | ||||||
Write off of equity investment in BBI | 662 | — | ||||||
Interest expense recorded in connection with fees paid for certain debt modifications and the termination of our senior secured credit facility | 20,940 | 1,091 | ||||||
Interest accretion associated with acquisition-related compensation charges | (406 | ) | 295 | |||||
Expense associated with extinguishment of debt | 3,480 | — | ||||||
|
|
|
| |||||
Non-GAAP adjusted interest and other income (expense), net(1) | $ | (125,828 | ) | $ | (152,692 | ) | ||
|
|
|
| |||||
| Nine Months Ended September 30, 2015 | Nine Months Ended September 30, 2014 | |||||||
Provision (benefit) for income taxes | $ | (10,009 | ) | $ | 69,273 | |||
Add: Income tax effects on Non-GAAP adjustments | 70,884 | (6,678 | ) | |||||
|
|
|
| |||||
Non-GAAP adjusted provision for income taxes, net(1) | $ | 60,875 | $ | 62,595 | ||||
|
|
|
| |||||
| Nine Months Ended September 30, 2015 | Nine Months Ended September 30, 2014 | |||||||
Equity earnings of unconsolidated entities, net of tax | $ | 10,320 | $ | 13,716 | ||||
Less adjustments: | ||||||||
Amortization of acquisition-related intangible assets | 314 | 430 | ||||||
Loss on sale of equity investment | — | 457 | ||||||
Income tax effects on items above | — | — | ||||||
|
|
|
| |||||
Non-GAAP adjusted equity earnings of unconsolidated entities, net of tax(1) | $ | 10,634 | $ | 14,603 | ||||
|
|
|
| |||||
| Nine Months Ended September 30, 2015 | Nine Months Ended September 30, 2014 | |||||||
Income (loss) from discontinued operations, net of taxes | $ | 216,777 | $ | (4,082 | ) | |||
Less adjustments: | ||||||||
Amortization of acquisition-related intangible assets | 559 | 22,541 | ||||||
Restructuring charges | (13 | ) | 4,039 | |||||
Goodwill impairment charge | — | 17,984 | ||||||
Fair value adjustments to acquisition-related contingent consideration | — | (26,321 | ) | |||||
Gain on Divestiture | (366,191 | ) | — | |||||
Income tax effects on items above | 148,056 | (5,857 | ) | |||||
|
|
|
| |||||
Non-GAAP adjusted income (loss) from discontinued operations, net of taxes(1) | $ | (812 | ) | $ | 8,304 | |||
|
|
|
| |||||
| Nine Months Ended September 30, 2015 | Nine Months Ended September 30, 2014 | |||||||
Net income (loss) attributable to non-controlling interests, net of tax | $ | 386 | $ | (136 | ) | |||
Less: Amortization of acquisition-related intangible assets, net of tax | 240 | 387 | ||||||
Income tax effects on items above | 63 | 88 | ||||||
|
|
|
| |||||
Non-GAAP adjusted net income attributable to non-controlling interests, net of tax(1) | $ | 563 | $ | 163 | ||||
|
|
|
| |||||
(1) The following is a summary of our non-GAAP adjusted measures included above: | ||||||||
Non-GAAP adjusted net revenue | $ | 1,840,230 | $ | 1,922,963 | ||||
Non-GAAP adjusted cost of net revenue | $ | 932,127 | $ | 956,362 | ||||
Non-GAAP adjusted research and development | $ | 79,578 | $ | 102,987 | ||||
Non-GAAP adjusted selling, general and administrative | $ | 492,686 | $ | 540,266 | ||||
Non-GAAP adjusted impairment and loss on dispositions, net | $ | — | $ | — | ||||
Non-GAAP adjusted interest and other income (expense), net | $ | (125,828 | ) | $ | (152,692 | ) | ||
Non-GAAP adjusted provision for income taxes | $ | 60,875 | $ | 62,595 | ||||
Non-GAAP adjusted equity earnings of unconsolidated entities, net of tax | $ | 10,634 | $ | 14,603 | ||||
Non-GAAP adjusted income (loss) from discontinued operations, net of tax | $ | (812 | ) | $ | 8,304 | |||
Non-GAAP adjusted net income attributable to non-controlling interests, net of tax | $ | 563 | $ | 163 | ||||
Alere Inc. and Subsidiaries
Reconciliations of Gross Profit/Margin to Non-GAAP Adjusted Gross Profit/Margin
(in thousands)
| Three Months Ended September 30, 2014 (1) | Three Months Ended June 30, 2015 | Three Months Ended September 30, 2015 | ||||||||||||||||||||||
Alere Consolidated | ||||||||||||||||||||||||
Net revenue | $ | 649,210 | $ | 629,156 | $ | 602,044 | ||||||||||||||||||
Adjustment related to acquired software license contracts | 324 | 200 | 430 | |||||||||||||||||||||
|
|
|
|
|
| |||||||||||||||||||
Non-GAAP adjusted net revenue | 649,534 | 629,356 | 602,474 | |||||||||||||||||||||
|
|
|
|
|
| |||||||||||||||||||
Cost of net revenue | 347,588 | 336,582 | 326,995 | |||||||||||||||||||||
Less adjustments: | ||||||||||||||||||||||||
Amortization of acquisition-related intangible assets | 15,684 | 13,112 | 16,132 | |||||||||||||||||||||
Stock-based compensation expense | 291 | 287 | 326 | |||||||||||||||||||||
Restructuring charges | 5,654 | 897 | 523 | |||||||||||||||||||||
|
|
|
|
|
| |||||||||||||||||||
Non-GAAP adjusted cost of net revenue | 325,959 | 322,286 | 310,014 | |||||||||||||||||||||
|
|
|
|
|
| |||||||||||||||||||
Non-GAAP adjusted gross profit/margin | $ | 323,575 | 49.8 | % | $ | 307,070 | 48.8 | % | $ | 292,460 | 48.5 | % | ||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
| Three Months Ended | Three Months Ended | Three Months Ended | ||||||||||||||||||||||
| September 30, 2014 (1) | June 30, 2015 | September 30, 2015 | ||||||||||||||||||||||
Professional Diagnostics Segment | ||||||||||||||||||||||||
Net product sales and services revenue | $ | 628,012 | $ | 598,817 | $ | 579,998 | ||||||||||||||||||
Adjustment related to acquired software license contracts | 324 | 200 | 430 | |||||||||||||||||||||
|
|
|
|
|
| |||||||||||||||||||
Non-GAAP adjusted net product sales and services revenue | 628,336 | 599,017 | 580,428 | |||||||||||||||||||||
|
|
|
|
|
| |||||||||||||||||||
Cost of net revenue | 329,013 | 312,068 | 292,156 | |||||||||||||||||||||
Less adjustments: | ||||||||||||||||||||||||
Amortization of acquisition-related intangible assets | 15,659 | 13,112 | 16,133 | |||||||||||||||||||||
Stock-based compensation expense | 291 | 287 | 326 | |||||||||||||||||||||
Restructuring charges | 5,654 | 897 | 523 | |||||||||||||||||||||
|
|
|
|
|
| |||||||||||||||||||
Non-GAAP adjusted cost of net revenue | 307,409 | 297,772 | 275,174 | |||||||||||||||||||||
|
|
|
|
|
| |||||||||||||||||||
Non-GAAP adjusted gross profit/margin | $ | 320,927 | 51.1 | % | $ | 301,245 | 50.3 | % | $ | 305,254 | 52.6 | % | ||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Note:
| (1) | Restated to reflect the impact of discontinued operations and the impact of a change in segment reporting |
Alere Inc. and Subsidiaries
Reconciliation of Net Income to Non-GAAP EBITDA
(in thousands)
| Three Months Ended | Nine Months Ended | |||||||
| September 30, 2015 | September 30, 2015 | |||||||
Net Income(1) | $ | 5,501 | $ | 234,992 | ||||
Less: Income from discontinued operations, net of tax | — | 216,777 | ||||||
|
|
|
| |||||
Income from continuing operations | 5,501 | 18,215 | ||||||
Adjustment related to acquired software license contracts | 430 | 877 | ||||||
Income tax provision (benefit) | (18,924 | ) | (10,009 | ) | ||||
Depreciation and amortization | 86,603 | 233,825 | ||||||
Interest, net(2) | 49,999 | 154,596 | ||||||
Non-cash stock-based compensation expense | 7,317 | 19,596 | ||||||
Non-cash fair value adjustments to acquisition-related contingent consideration | 957 | (51,910 | ) | |||||
Non-cash write-off of an investment | 662 | 662 | ||||||
Impairment and gain (loss) on dispositions, net | 2,074 | 42,408 | ||||||
|
|
|
| |||||
Non-GAAP EBITDA | $ | 134,619 | $ | 408,260 | ||||
|
|
|
| |||||
| (1) | Net income for the three months and nine months ended September 30, 2015 includes non-interest related restructuring charges of $2.3 million and $11.4 million, respectively, and $1.9 million and $6.5 million of costs associated with business dispositions, respectively, which have not been added back for purposes of computing non-GAAP EBITDA. The three months and nine months ended September 30, 2015 also includes $0.2 million and $0.3 million, respectively, of acquisition-related costs. |
| (2) | Includes $3.5 million of expense associated with the extinguishment of debt during the nine months ended September 30, 2015. |
Alere Inc. and Subsidiaries
Reconciliation of Net Cash Provided by Operating Activities to Non-GAAP Free Cash Flow
(in thousands)
| Three Months Ended | Nine Months Ended | |||||||
| September 30, 2015 | September 30, 2015 | |||||||
Net cash provided by operating activities | $ | 104,724 | $ | 137,250 | ||||
Capital expenditures | (20,663 | ) | $ | (67,947 | ) | |||
|
|
|
| |||||
Non-GAAP free cash flow | $ | 84,061 | $ | 69,303 | ||||
|
|
|
| |||||